MoonLake Immunotherapeutics (MLTX) Research
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
Market snapshot
- Symbol
- MLTX
- Price
- $19.21
- Day change
- +0.10%
- Market cap
- $1.4B
- P/E ratio
- -5.33x
- 52-week range
- 5.95-62.75
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $28.50
Recent news
- FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars
MoonLake Immunotherapeutics (NASDAQ:MLTX) shares are up during Monday's trading session, trading higher as the company is reporting positive outcomes from its final pre-BLA meeting with the FDA regarding its sonelokimab (SLK) program for hidradenitis suppurativa (HS).
- MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket
Shares of MoonLake Immunotherapeutics bounded higher Monday after the biotech said it met with the Food and Drug Administration in April.
Peer companies
Recent insider activity
- Bodenstedt Matthias — S-Sale (15082 shares) on 2026-06-17
- Bodenstedt Matthias — S-Sale (2794 shares) on 2026-06-18
- Phillips Andrew John — A-Award (22195 shares) on 2026-06-17
- Loy Spike — A-Award (22195 shares) on 2026-06-17
- Moukheibir Catherine — A-Award (22195 shares) on 2026-06-17
Open MoonLake Immunotherapeutics (MLTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.